Harmony Biosciences Stock Up as FDA Rejects to Reevaluate Narcolepsy Treatment Patent
By Sabela Ojea
Shares of Harmony Biosciences Holdings on Monday rose after the Food and Drug Administration denied reviewing the company's patent over a narcolepsy treatment.
At 2:04 pm E.T., shares were up 6.7% at $34.71. The stock has, however, declined 38% since the year started.
The drugmaker said the FDA didn't validate claims within the patent covering the active ingredient in the medicine Wakix, in line with its expectations.
"This decision not only underscores our confidence in the strength of the Wakix patent portfolio but also reinforces our belief in the potential of the Wakix franchise," Harmony Biosciences said, noting that its treatment "represents a billion-dollar plus opportunity in narcolepsy alone."
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
August 28, 2023 14:31 ET (18:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States